Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2016
Price : $35 *
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 20 Apr 2016 Status changed from active, no longer recruiting to completed.
- 05 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 Dec 2013 New trial record